{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"46","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the percentage of patients who are alive and have not developed relapse/progression of primary disease or clinical grade III-IV acute graft-versus- host disease (GVHD) or chronic GVHD requiring systemic treatment. Subjects who receive all 4 doses of carfilzomib at the maximum tolerated dose level will be considered evaluable for endpoint analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered 20 mg/m\\^2 on days 1 and 2; 36 mg/m\\^2 of Carfilzomib on days 6 and 7.","id":"OG000","title":"Dose Level 3 - Maximum Dose Carfilzomib 36 mg/m^2 IV"}],"paramType":"NUMBER","populationDescription":"Subjects who have received all 4 doses of carfilzomib at the maximum tolerated dose (MTD) level (dose level 3, 36 mg/m\\^2): 39 subjects total. Note: three subjects who completed 4 doses of carfilzomib at the MTD during the phase 1 portion of the study were included in phase 2 analysis of the primary outcome measure.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Phase II: Kaplan-Meier Estimate of the Percentage of Patients Who Are Alive and Have Not Developed Any \"Event\"","type":"PRIMARY","unitOfMeasure":"percentage of participants"}